Biotest AG (BIESF)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist Biotest AG (BIESF) ein Healthcare-Unternehmen mit einer Bewertung von 0. Bewertet mit 48/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 16. März 2026Biotest AG (BIESF) Gesundheitswesen & Pipeline-Uebersicht
Biotest AG, a subsidiary of Grifols, S.A., operates in the biotechnology sector, developing and marketing biological medicines for hematology, clinical immunology, and intensive care. The company's focus on plasma-derived products and therapies for rare diseases positions it within a specialized segment of the global healthcare market, primarily serving Germany and international markets.
Investmentthese
Biotest AG, as a subsidiary of Grifols, presents a focused investment opportunity within the specialized field of plasma-derived therapies. The company's established product portfolio in hematology, immunology, and intensive care provides a stable revenue base. Growth catalysts include the potential expansion of existing product lines and the introduction of new therapies. However, the company's negative profit margin of -7.1% and high P/E ratio of -36.18 indicate potential challenges in achieving profitability. The company's beta of 0.00 suggests low volatility relative to the market. The dividend yield is 0.13%.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $1.60 billion reflects Biotest AG's current valuation within the biotechnology sector.
- Negative P/E ratio of -36.18 indicates that the company is currently not profitable.
- Gross margin of 20.1% shows the percentage of revenue exceeding the cost of goods sold.
- Dividend yield of 0.13% provides a small return for investors.
- Biotest AG operates as a subsidiary of Grifols, S.A., providing financial backing and strategic direction.
Wettbewerber & Vergleichsunternehmen
Staerken
- Specialized expertise in plasma-derived therapies.
- Established product portfolio in hematology, immunology, and intensive care.
- Stringent regulatory approvals and compliance.
- Operates as a subsidiary of Grifols, S.A.
Schwaechen
- Negative profit margin.
- High P/E ratio.
- Dependence on plasma supply.
- Limited geographic diversification.
Katalysatoren
- Upcoming: Clinical trial results for Trimodulin in community-acquired pneumonia and COVID-19.
- Upcoming: Regulatory approvals for new immunoglobulin therapies.
- Ongoing: Expansion into emerging markets in Asia and Latin America.
- Ongoing: Strategic partnerships and acquisitions to expand product portfolio.
- Ongoing: Advancements in plasma fractionation technology to improve efficiency.
Risiken
- Potential: Competition from other biotechnology companies in the plasma-derived therapies market.
- Potential: Stringent regulatory requirements and compliance costs.
- Potential: Fluctuations in plasma supply and pricing.
- Ongoing: Patent expirations and generic competition.
- Ongoing: Negative profit margin and high P/E ratio.
Wachstumschancen
- Expansion of Trimodulin for Community-Acquired Pneumonia (CAP) and COVID-19: Trimodulin represents a significant growth opportunity for Biotest AG. The global market for CAP treatment is projected to reach billions of dollars, while the ongoing need for COVID-19 therapies further expands the potential market. Biotest's clinical trials and regulatory approvals will be critical milestones in capturing this market share. Success in these areas could significantly boost revenue and market position.
- Development of Novel Immunoglobulin Therapies: Biotest AG's focus on immunoglobulin therapies, such as Intratect and IgG Next Generation, presents a substantial growth opportunity. The global market for immunoglobulin therapies is expanding due to the increasing prevalence of immune deficiency disorders and autoimmune diseases. Biotest's research and development efforts in this area, coupled with successful clinical trials and regulatory approvals, could lead to the introduction of new and improved therapies, driving revenue growth.
- Geographic Expansion into Emerging Markets: Biotest AG has the opportunity to expand its geographic presence into emerging markets, particularly in Asia and Latin America. These regions are experiencing growing demand for plasma-derived therapies due to increasing healthcare expenditure and improving access to healthcare services. By establishing partnerships, distribution networks, and regulatory approvals in these markets, Biotest can tap into new revenue streams and diversify its geographic footprint.
- Strategic Partnerships and Acquisitions: Biotest AG can pursue strategic partnerships and acquisitions to expand its product portfolio, access new technologies, and strengthen its market position. Collaborations with other biotechnology companies, research institutions, and healthcare providers can accelerate the development and commercialization of new therapies. Acquisitions of complementary businesses can broaden Biotest's product offerings and geographic reach, creating synergies and enhancing shareholder value.
- Advancements in Plasma Fractionation Technology: Investing in advanced plasma fractionation technologies can improve the efficiency and yield of plasma-derived products, reducing production costs and increasing profitability. By adopting innovative technologies such as membrane chromatography and continuous processing, Biotest can optimize its manufacturing processes and enhance its competitive advantage. These advancements can also lead to the development of new and improved plasma-derived therapies, further driving revenue growth.
Chancen
- Expansion of Trimodulin for CAP and COVID-19.
- Development of novel immunoglobulin therapies.
- Geographic expansion into emerging markets.
- Strategic partnerships and acquisitions.
Risiken
- Competition from other biotechnology companies.
- Stringent regulatory requirements.
- Fluctuations in plasma supply and pricing.
- Patent expirations and generic competition.
Wettbewerbsvorteile
- Specialized expertise in plasma-derived therapies.
- Established product portfolio in hematology, immunology, and intensive care.
- Stringent regulatory approvals and compliance.
- Proprietary manufacturing processes and technologies.
Ueber BIESF
Biotest AG, founded in 1946 and headquartered in Dreieich, Germany, is a biotechnology company specializing in the development, manufacture, and sale of biological medicines. Originally known as Biotest Serum-Institut GmbH, the company changed its name in 1986. Its core business revolves around plasma-derived products used in hematology, clinical immunology, and intensive care medicine. Key products include treatments for hemophilia A and B (Haemoctin, Vihuma, and Haemonine), therapies for cytomegalovirus infections (Cytotect CP biotest), and prophylaxis against hepatitis B (Fovepta and Hepatect). Additionally, Biotest offers Intratect and IgG Next Generation for immune deficiencies and autoimmune diseases, Varitect for varicella zoster virus infections, and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides products like Albiomin and Biseko for blood volume restoration, Cofact for clotting factor deficiencies, Fibrinogen for congenital fibrinogen deficiency, Trimodulin for pneumonia and COVID-19, and Pentaglobin for bacterial infections. As of January 21, 2022, Biotest AG operates as a subsidiary of Grifols, S.A., a global healthcare company and a leading producer of plasma-derived medicines.
Was das Unternehmen tut
- Develops biological medicines for hematology.
- Manufactures biological medicines for clinical immunology.
- Sells biological medicines for intensive care medicine.
- Offers treatments for hemophilia A and B.
- Provides therapies for cytomegalovirus infections.
- Offers prophylaxis against hepatitis B.
- Develops immunoglobulin therapies for immune deficiencies and autoimmune diseases.
- Provides products for blood volume restoration and clotting factor deficiencies.
Geschaeftsmodell
- Develops and manufactures plasma-derived products.
- Sells biological medicines directly to hospitals and healthcare providers.
- Generates revenue through product sales in Germany and internationally.
- Focuses on therapies for rare diseases and specialized medical conditions.
Branchenkontext
Biotest AG operates within the biotechnology industry, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market for plasma-derived therapies is driven by the increasing prevalence of chronic diseases, advancements in diagnostic technologies, and growing demand for specialized treatments. Biotest's focus on hematology, immunology, and intensive care positions it within specific segments of this market. Competitors include other biotechnology companies specializing in plasma-derived products and therapies for rare diseases. The industry is subject to regulatory oversight by agencies such as the European Medicines Agency (EMA) and other international regulatory bodies.
Wichtige Kunden
- Hospitals and clinics.
- Healthcare providers.
- Patients with hematological disorders.
- Patients with immunological disorders.
- Patients in intensive care units.
Finanzdaten
Chart & Info
Biotest AG (BIESF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer BIESF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer BIESF.
Kursziele
Wall-Street-Kurszielanalyse fuer BIESF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von BIESF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Jorg Schuttrumpf
CEO
Jorg Schuttrumpf is the CEO of Biotest AG. Information regarding his detailed career history, education, and previous roles is not available in the provided context. As the CEO, he is responsible for the overall strategic direction and operational performance of the company, overseeing the development, manufacturing, and commercialization of biological medicines.
Erfolgsbilanz: Information regarding Jorg Schuttrumpf's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided context. His role involves guiding Biotest AG in its focus on plasma-derived products and therapies for rare diseases, as well as navigating the competitive landscape of the biotechnology industry.
BIESF OTC-Marktinformationen
The OTC Other tier, where BIESF trades, represents the lowest tier of the OTC market. Companies in this tier may not meet minimum financial standards and have limited reporting requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with unproven business models, early-stage ventures, or those facing financial distress. Investors should exercise caution and conduct thorough due diligence before investing in companies on this tier, as the risk of fraud and manipulation is higher.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases information asymmetry and the risk of making investment decisions based on incomplete or unreliable data.
- Lower liquidity can lead to price volatility and difficulties in buying or selling shares at desired prices.
- The OTC Other tier has a higher risk of fraud and manipulation compared to major exchanges.
- Biotest AG's financial performance and prospects may be more uncertain due to the limited availability of information.
- The company's compliance with regulatory requirements may be less stringent compared to companies listed on major exchanges.
- Verify the company's registration and legal status in Germany.
- Obtain and review the company's financial statements, if available, from German regulatory filings or other sources.
- Assess the company's business model, products, and market position.
- Evaluate the company's management team and corporate governance practices.
- Research the company's history and track record, including any past legal or regulatory issues.
- Understand the risks associated with investing in OTC stocks, including limited disclosure and liquidity.
- Consult with a financial advisor before making any investment decisions.
- Biotest AG is a subsidiary of Grifols, S.A., a reputable global healthcare company.
- The company has a long operating history, having been founded in 1946.
- Biotest AG develops and manufactures biological medicines for critical medical conditions.
- The company's products are subject to regulatory approvals and compliance.
- Biotest AG has a team of employees dedicated to research, development, and manufacturing.
Biotest AG Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for BIESF?
Biotest AG (BIESF) currently holds an AI score of 48/100, indicating low score. Key strength: Specialized expertise in plasma-derived therapies.. Primary risk to monitor: Potential: Competition from other biotechnology companies in the plasma-derived therapies market.. This is not financial advice.
How frequently does BIESF data refresh on this page?
BIESF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BIESF's recent stock price performance?
Recent price movement in Biotest AG (BIESF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized expertise in plasma-derived therapies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BIESF overvalued or undervalued right now?
Determining whether Biotest AG (BIESF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BIESF?
Before investing in Biotest AG (BIESF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BIESF to a portfolio?
Potential reasons to consider Biotest AG (BIESF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Specialized expertise in plasma-derived therapies.. Additionally: Established product portfolio in hematology, immunology, and intensive care.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of BIESF?
Yes, most major brokerages offer fractional shares of Biotest AG (BIESF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BIESF's earnings and financial reports?
Biotest AG (BIESF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for BIESF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be subject to change.
- AI analysis is pending for BIESF.
- OTC market data may be less reliable than data for exchange-listed stocks.